Use of mesenchymal stem cells in an experimental model of metabolic syndrome complicated with cardiomyopathy

Document Type : Original Article

Authors

1 Department of Biochemistry, Faculty of Medicine, Sohag University.

2 Department of Biochemistry, Faculty of Medicine, Cairo University.

3 Department of Biochemistry, Faculty of Medicine, Assuit University.

Abstract

Obesity is a major global health issue. Most obese patients develop metabolic syndrome, a cluster of clinical features characterized by hypertension, insulin resistance and dyslipidemia this pre-diabetic condition has recognized as an independent risk factor for cardiovascular diseases, particularly hypertension, atherosclerosis and diabetic cardiomyopathy. MSC can differentiate into many mesenchymal cells as cardiomyocytes. The application of MSCs in the treatment of DC in recent years offers promising results. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients.Recently, a substantial number of clinical trials have proven that stem cell therapy is safe. Infusion of bone marrow-derived stem cells (BMCs) represents the greatest number of clinical studies for MI. This review highlights the use of mesenchymal stem cells in metabolic syndrome and diabetic cardiomyopathy  

References

  1. of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) The Journal of the American Medical Association. 2001;285(19):2486–2497.
  2. Alberti K. G., Eckel R. H., Grundy S. M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640–1645.
  3. Haffner S., Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108(13):1541–1545.
  4. Silva D, Souza B, Azevedo C, Vasconcelos J, Carvalho R, Soares M, and Santos R. Intramyocardial transplantation of cardiac mesenchymal stem cells reduces myocarditis in a model of chronic Chagas disease cardiomyopathy. Stem Cell Research & Therapy. 2014, 5:81.
  5. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation. 2006, 114:1522–30.
  6. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006, 98:596–605.
  7. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy afte
  8. replenishment of local vascular endothelial growth factor. Circulation. 2005, 111:2073–85.
  9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells.The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8:315–7.
  10. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284:143–7.
  11. Tirino V, Paino F, d’Aquino R, Desiderio V, De Rosa A, Papaccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev. 2011, 7:608–15.
  12. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 2011, 29:5–10.
  13. Davey GC, Patil SB, Loughlin AO and Brien TO. Mesenchymal stem cell-based treatment for microvascular and secondary complications of Diabetes mellitus. Frontiers in endocrinology. 2014, 5:1-15.
  14. Haidar Ym and Cosman Bc (2011): Obesity epidemiology. Clin Colon Rectal Surg; 24(4): 205-210.
  15. Bonora E., Kieciil S.,Willem J., et al .(2003):metabolic syndrome; epidemiology and more extensive phenotypic description. Cross- sectional data from the Bruned, Study. Int J., Obes Related Metab disord 27,1283-1289.
  16. Obunai K, Ianis, and Dangas Gd (2007): Cardiovascular morbidity and mortality of metabolic syndrome . Med Clin North Am 91, 1169-1184.
  17. Rubler S., Dlugash J., Yuceoglu Yz., et al. (1972): New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30, 595-602
  18. Asghar O., Al-Sunni A., Khavandi K., et al. (2009): Diabetic cardiomyopathy. Clin Sci (Lond) 116, 741-760.
  19. Boudina S and Abel ED. (2010): Diabetic cardiomyopathy causes and effects. Rev Endocr Metab Disord., 11:31-39
  20. Miki T., Yuda S., Kouzu H., et al. (2013): Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18, 149-166
  21. Bernardi S., Severini Gm., Zauli G., et al. (2012): Cell-based therapies for diabetic complications. Exp Diabetes Res 2012, 872504.
  22. Jones Da, Choudry F, And Mathur A (2012): Cell therapy in cardiovascular disease: the national society journals present selected research that has driven recent advances in clinical cardiology. Heart 98, 1626-1631.
  23. ANKRUM J, and KARP JM (2010): Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16, 203-209.
  24. Haffner S., Taegtmeyer H. (2003): Epidemic obesity and the metabolic syndrome. Circulation.;108(13):1541–1545.
  25. AlbertiK. G., Eckel R. H., Grundy S. M., et al. (2009): Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation.; 120(16): 1640–1645.
  26. Silva D., Souza B., Azevedo C., et al. (2014): Intramyocardial transplantation of cardiac mesenchymal stem cells reduces myocarditis in a model of chronic Chagas disease cardiomyopathy. Stem Cell Research & Therapy., 5:81.
  27. Secchiero P., Candido R., Corallini F., et al. (2006): Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation., 114:1522–30.
  28. Poornima IG, Parikh P, Shannon RP. (2006): Diabetic cardiomyopathy: the search   for a unifying hypothesis. Circ Res., 98:596–605.
  29. YoonYS., Uchida S., Masuo O., et al. (2005): Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy. Circulation., 111:2073–85

 

Sohag Medical Journal
Volume 22, Issue 1
January 2018
Pages 207-211

Files

Share

How to cite

Statistics